ALSO IN THIS MONTH'S ISSUE

• What’s Next In Biotech’s Deal Playbook?

  Facing deflated investor confidence, precipitously low stock market runs, rising interest rates, and commercial setbacks, underperforming biotech companies and their boards need to be resourceful to stay afloat. The right deal-making strategy can drive the business forward.

• What To Consider When Acquiring A Biopharma Manufacturing Facility

  In this article, I share the considerations you should keep in mind when acquiring a stand-alone biopharma manufacturing facility, using a real-life example from my experience.

• Biopharma In China: The Emerging Global Force Of Domestic Suppliers

  A major factor in the emerging domestic competition is the Chinese drug industry’s response to cost pressures being implemented, such as the volume-based procurement (VBP) policy.

• How Cell And Gene Therapies Are Advancing Collaborations In Biopharma

  The last time I wrote for Life Science Leader, I highlighted the importance of collaboration in the field of regenerative medicine. Here, I wanted to reassess how these collaborations are elevating the state of science as well as diversity initiatives with a focus on cell and gene therapies.